- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02671955
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
March 26, 2018 updated by: Janssen Research & Development, LLC
An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
Study Overview
Detailed Description
The purpose of this study is to see if JNJ-61610588 is safe and useful for treating participants with advanced cancer.
This study consists of up to 4 parts.
Part 1 will determine what dose of JNJ-61610588 can be given safely to advanced cancer participants.
Part 2 will look at how participants with metastatic non-small cell lung cancer respond to a safe dose of JNJ-61610588.
Parts 3 and 4 will test whether the dose of JNJ-61610588 identified in Part 1 is a safe and effective therapy for participants with specific types of advanced cancers (lung, pancreas, cervical, colorectal, head and neck).
Participants will receive study drug in an outpatient setting.
Participants safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant has a solid tumor. Parts 2 and 3 are limited to participants with non-small cell lung cancer. Part 4 is limited to participants with small cell lung, head and neck, pancreatic, colorectal, and cervical cancers
- Tumor progression following at least one prior standard therapy
- The participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part 1 only
- The participant is willing to consent to provide a tumor tissue sample (fresh biopsy) before (Parts 2 and 3) and after (Part 2 only) receiving the study drug
- The participant is able to carry out daily life activities without difficulty
- The participant does not have significant side effects from previous anti-cancer treatment
- The participant has adequate organ and blood cell counts
- Sexually active participants must use medically acceptable methods of contraception during the course of this study
Exclusion Criteria:
- The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study
- The participant has an untreated brain tumor
- Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics
- The participant has high blood pressure or diabetes that is not well-controlled with medication
- History of clinically significant heart problems
- History of severe side effects toimmunotherapy
- The participant is pregnant, breastfeeding, or planning to become pregnant or father a child
- Positive for Hepatitis B, Hepatitis C, or HIV
- The participant has received anticoagulant therapy with the exception of aspirin within 1 week of starting the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Dose Escalation
Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression.
Dose escalation will continue until the maximum tolerated dose is reached.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
Experimental: Part 2: Biomarker Evaluation
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
Experimental: Part 3: Dose Expansion
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
Experimental: Part 4: Dose Expansion
Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Dose Limiting Toxicity (DLT)
Time Frame: Approximately 2.5 years
|
The Dose Limiting Toxicity (DLT) is based on adverse events and includes unacceptable hematologic toxicity, unacceptable non-hematologic toxicity of Grade 3 or higher, and treatment delay greater than 2 weeks.
|
Approximately 2.5 years
|
Number of Participants with Adverse Events (AEs) and Serious AEs
Time Frame: Approximately 2.5 years
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Approximately 2.5 years
|
Change From Baseline in Pharmacodynamic Blood Biomarkers- Total Blood Cell Counts
Time Frame: Approximately 2.5 years
|
Standard hematology laboratory tests will be used to evaluate total blood cell counts in blood samples collected pre- and posttreatment.
|
Approximately 2.5 years
|
Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of Monocyte Activation
Time Frame: Approximately 2.5 years
|
Flow cytometry will be used to evaluate markers of monocyte activation in blood samples collected pre- and posttreatment.
|
Approximately 2.5 years
|
Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of T Cell Activation
Time Frame: Approximately 2.5 years
|
Flow cytometry will be used to evaluate markers of T cell activation in blood samples collected pre- and posttreatment.
|
Approximately 2.5 years
|
Change From Baseline in Pharmacodynamic Tissue Biomarkers- Protein Expression of VISTA (V-domain Ig suppressor of T cell activation)
Time Frame: Approximately 2.5 years
|
Pre- and posttreatment tissue samples will be stained by immunohistochemistry for protein expression of VISTA.
|
Approximately 2.5 years
|
Change From Baseline in Pharmacodynamic Tissue Biomarkers- Markers Associated With Immune Infiltrate Including CD3, CD4, CD8, Forkhead box P3, CD68, and PD-L1.
Time Frame: Approximately 2.5 years
|
Pre- and posttreatment tissue samples will be stained by immunohistochemistry for markers associated with immune infiltrate including CD3, CD4, CD8, forkhead box P3, CD68, and PD-L1.
|
Approximately 2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Serum Concentration (Cmax) of JNJ-61610588
Time Frame: Approximately 2.5 years
|
The Cmax is the maximum observed serum concentration of JNJ-61610588.
|
Approximately 2.5 years
|
Elimination Half-Life (t1/2)
Time Frame: Approximately 2.5 years
|
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Approximately 2.5 years
|
Area Under the Serum Concentration-Time Curve From t1 to t2 Time (AUC[t1-t2]) of JNJ-61610588
Time Frame: Approximately 2.5 years
|
The AUC(t1-t2) is the area under the serum JNJ-61610588 concentration-time curve from time t1 to t2.
|
Approximately 2.5 years
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
Time Frame: Approximately 2.5 years
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
|
Approximately 2.5 years
|
Number of Participants With Anti-JNJ-61610588 Antibodies
Time Frame: Approximately 2.5 years
|
Plasma levels of antibodies to JNJ-61610588 for evaluation of potential immunogenicity.
|
Approximately 2.5 years
|
Assessment of Anti-Tumor Activity, as Assessed by the Overall Response Rate (ORR)
Time Frame: Approximately 2.5 years
|
Anti-tumour activity as assessed by the ORR based on Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1.
|
Approximately 2.5 years
|
Assessment of Anti-Tumor Activity, as Assessed by the Overall Response Rate (ORR)
Time Frame: Approximately 2.5 years
|
Anti-tumour activity as assessed by the ORR based on Immune-Related Response Criteria (irRC).
|
Approximately 2.5 years
|
Assessment of Anti-Tumor Activity, as Assessed by Duration of Response
Time Frame: Approximately 2.5 years
|
Anti-tumour activity as assessed by the duration of response.
|
Approximately 2.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
January 11, 2016
First Submitted That Met QC Criteria
January 29, 2016
First Posted (Estimate)
February 2, 2016
Study Record Updates
Last Update Posted (Actual)
March 27, 2018
Last Update Submitted That Met QC Criteria
March 26, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108083
- 61610588LUC1001 (Other Identifier: Janssen Research & Development, LLC)
- 2016-001903-22 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Bristol-Myers SquibbRecruitingAdvanced CancerUnited States, Spain, Belgium, Argentina, Korea, Republic of, Japan
Clinical Trials on JNJ-61610588
-
Janssen Research & Development, LLCRecruitingLymphoma, Non-HodgkinDenmark, Israel, Spain, Australia
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Johnson & Johnson Enterprise Innovation Inc.RecruitingAdvanced Solid TumorsUnited States
-
Janssen Cilag N.V./S.A.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Research & Development, LLCActive, not recruitingLymphoma, Non-Hodgkin | Chronic Lymphocytic LeukemiaUnited States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine